

Published in final edited form as:

*Nature*. 2011 February 10; 470(7333): 269–273. doi:10.1038/nature09677.

## SMAD4–dependent barrier constrains prostate cancer growth and metastatic progression

Zhihu Ding<sup>1,2,3,4</sup>, Chang–Jiun Wu<sup>1,2,3,4,\*</sup>, Gerald C. Chu<sup>1,2,5,\*</sup>, Yonghong Xiao<sup>1,2</sup>, Dennis Ho<sup>1,2,3,4</sup>, Jingfang Zhang<sup>6</sup>, Samuel R. Perry<sup>1,2</sup>, Emma S. Labrot<sup>1,2</sup>, Xiaoqiu Wu<sup>2,7</sup>, Rosina Lis<sup>2,7</sup>, Yujin Hoshida<sup>8,9</sup>, David Hiller<sup>10</sup>, Baoli Hu<sup>1,2</sup>, Shan Jiang<sup>1,2</sup>, Hongwu Zheng<sup>1,2,3,4</sup>, Alexander H. Stegh<sup>1,2,3,4</sup>, Kenneth L. Scott<sup>1,2,3,4</sup>, Sabina Signoretti<sup>11</sup>, Nabeel Bardeesy<sup>12</sup>, Y. Alan Wang<sup>1,2</sup>, David E. Hill<sup>3,13</sup>, Todd R. Golub<sup>8,9</sup>, Meir J. Stampfer<sup>15,16,17</sup>, Wing H. Wong<sup>10</sup>, Massimo Loda<sup>2,5,7</sup>, Lorelei Mucci<sup>15,17</sup>, Lynda Chin<sup>1,2,3,4,14</sup>, and Ronald A. DePinho<sup>1,2,3,4</sup>

<sup>1</sup>Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA

<sup>2</sup>Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA

<sup>3</sup>Department of Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA

<sup>4</sup>Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA

<sup>5</sup>Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA

<sup>6</sup>McArdle Lab for Cancer Research, University of Wisconsin, Madison, Wisconsin 53706-1526, USA

<sup>7</sup>Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA

<sup>8</sup>Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA

<sup>9</sup>The Eli and Edythe L. Broad Institute, Massachusetts Institute of Technology and Harvard University, Cambridge, Massachusetts 02142, USA

<sup>10</sup>Department of Statistics, Stanford University, Stanford, California 94305, USA

<sup>11</sup>Renal Cancer Program, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts 02115, USA

<sup>12</sup>Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, Massachusetts 02114, USA

©2011 Macmillan Publishers Limited. All rights reserved

Correspondence and requests for materials should be addressed to ron\_depinho@dfci.harvard.edu or lynda\_chin@dfci.harvard.edu.

\*These authors contributed equally to this work.

**Author Information** The microarray data have been deposited in the GEO database with accession number GSE25140. Reprints and permissions information is available at [www.nature.com/reprints](http://www.nature.com/reprints). The authors declare competing financial interests: details accompany the full-text HTML version of the paper at [www.nature.com/nature](http://www.nature.com/nature). Readers are welcome to comment on the online version of this article at [www.nature.com/nature](http://www.nature.com/nature).

Supplementary Information is linked to the online version of the paper at [www.nature.com/nature](http://www.nature.com/nature).

**Author Contributions** Z.D. designed and performed the experiments. L.C. and R.A.D. supervised experiments and computational analysis and contributed as senior authors. C.J.W., Y.X., Y.H., D.H., T.R.G., M.J.S., W.H.W. and L.M. performed the computational analysis. G.C.C. provided pathology analyses. X.W., R.L., S.S. and M.L. performed TMA staining and quantification. N.B. generated *Smad4L* mouse allele. D.E.H. provided the human ORFeome clones. D.H., J.Z., S.R.P., E.S.L., B.H., S.J., H.Z., A.H.S. and K.L.S. performed the experiments. Y.A.W. contributed to the writing of the manuscript.

<sup>13</sup>Center for Cancer Systems Biology and Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA

<sup>14</sup>Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA

<sup>15</sup>Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts 02115, USA

<sup>16</sup>Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts 02115, USA

<sup>17</sup>Channing Laboratory, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA

## Abstract

Effective clinical management of prostate cancer (PCA) has been challenged by significant intratumoural heterogeneity on the genomic and pathological levels and limited understanding of the genetic elements governing disease progression<sup>1</sup>. Here, we exploited the experimental merits of the mouse to test the hypothesis that pathways constraining progression might be activated in indolent *Pten*-null mouse prostate tumours and that inactivation of such progression barriers in mice would engender a metastasis-prone condition. Comparative transcriptomic and canonical pathway analyses, followed by biochemical confirmation, of normal prostate epithelium versus poorly progressive *Pten*-null prostate cancers revealed robust activation of the TGF $\beta$ /BMP–SMAD4 signalling axis. The functional relevance of SMAD4 was further supported by emergence of invasive, metastatic and lethal prostate cancers with 100% penetrance upon genetic deletion of *Smad4* in the *Pten*-null mouse prostate. Pathological and molecular analysis as well as transcriptomic knowledge-based pathway profiling of emerging tumours identified cell proliferation and invasion as two cardinal tumour biological features in the metastatic *Smad4*/*Pten*-null PCA model. Follow-on pathological and functional assessment confirmed cyclin D1 and SPP1 as key mediators of these biological processes, which together with PTEN and SMAD4, form a four-gene signature that is prognostic of prostate-specific antigen (PSA) biochemical recurrence and lethal metastasis in human PCA. This model-informed progression analysis, together with genetic, functional and translational studies, establishes SMAD4 as a key regulator of PCA progression in mice and humans.

---

Adenocarcinoma of the prostate (PCA) is the most common form of cancer and the second leading cause of cancer death in American men<sup>2</sup>. Current methods of stratifying tumours to predict outcome are based on clinical-pathological factors including Gleason grade, PSA and tumour stage<sup>3</sup>. These parameters are widely considered inadequate, which has motivated the genetic and biological study of PCA progression with the goal of identifying progression risk biomarkers capable of improving patient management<sup>4</sup>.

Genetic studies of human PCA has identified signature pathogenetic events<sup>5</sup>, a number of which have been validated and mechanistically defined in genetically engineered mouse models of PCA<sup>6</sup>. Prostate-specific *Pten* deletion (*Pten*<sup>pc-/-</sup>) results in prostate intraepithelial neoplasia (PIN) which, following a long latency, can progress to high-grade adenocarcinoma, albeit with minimally invasive and metastatic features<sup>7-10</sup>. To understand this feeble progression phenotype, we conducted transcriptome comparison of *Pten*<sup>pc-/-</sup> PIN relative to wild-type prostate epithelium (Supplementary Data 1). In addition to the expected PI3K and p53 (also known as TRP53) pathway representation<sup>8</sup>, knowledge-based pathway analysis revealed prominent TGF $\beta$ /BMP signalling in *Pten*<sup>pc-/-</sup> PIN (Supplementary Fig. 1). Immunohistochemical and western blotting analyses of *Smad4* expression confirmed robust increase in *Pten*<sup>pc-/-</sup> PIN compared to wild-type prostate epithelium (Fig. 1a, b). In line with reported down-regulated expression of SMAD4 in a subset of human primary prostate tumours<sup>11</sup>, Oncomine expression analysis showed consistent *SMAD4* downregulation in

human PCA metastasis (Fig. 1c and Supplementary Fig. 2). Loss of *SMAD4* in advanced PCA is further supported by recent report of frequent epigenetic silencing of the *SMAD4* promoter in advanced disease<sup>12</sup>. On the functional level, *SMAD4* knockdown in PC3 showed significantly enhanced frequency of metastases to the lung from renal capsule implantation (Fig. 1d and Supplementary Fig. 3). These observations prompted speculation that a SMAD4-dependent barrier constrains PCA progression.

To obtain genetic evidence that *Smad4* extinction enables progression, we engineered mice harbouring *Pb-Cre4* and conditional knockout alleles of *Pten* and/or *Smad4* (designated *Pten<sup>pc-/-</sup>* and *Smad4<sup>pc-/-</sup>*) and confirmed prostate-specific deletion (Supplementary Fig. 4). At 7 weeks of age, both *Pten<sup>pc-/-</sup>* and *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* models develop low-grade PIN (Fig. 2a). Consistent with previous studies<sup>7,8</sup>, *Pten<sup>pc-/-</sup>* mice acquired invasive features after 19 weeks of age and most survived beyond 1 year of age (Fig. 2b). In contrast, *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* mice developed focally invasive PCA by 11 weeks (Fig. 2a, arrow) and highly aggressive invasive PCA with stromal reaction by 15 weeks of age (Fig. 2a and Supplementary Fig. 5). All *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* mice died by 32 weeks of age due largely to bladder outlet obstruction which caused hydronephrosis and renal failure (Fig. 2b,c and Supplementary Fig. 6), whereas *Smad4<sup>pc-/-</sup>* mice showed no prostate neoplasia beyond 2 years of age (Fig. 2b and Supplementary Fig. 7).

Molecular pathological analysis of PCA-bearing *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* mice showed metastatic spread of Krt8 and androgen receptor-positive (Krt8<sup>+</sup>, Ar<sup>+</sup>) tumour nodules to draining lumbar lymph nodes in 25/25 cases and lung metastases in 3/25 cases (0.3–3 mm diameter metastatic nodules) (Fig. 2d, Supplementary Fig. 8 and Supplementary Table 1). The histological features of these metastases resembled those of the primary prostate tumour (Fig. 2d). These observations are in contrast to the *Pten<sup>pc-/-</sup>* PCA-bearing mice which never developed metastatic lesions when examined at 1 year of age ( $n = 10$ ), and only two mice (2/8) older than 1.5 years of age contained a solitary lumbar lymph node metastasis and one of these mice also possessed a solitary lung micrometastasis (Supplementary Table 1), a constrained progression phenotype that aligns with previous reports<sup>7-9</sup>. Similarly, 0/20 *Pten<sup>pc-/-</sup> p53<sup>pc-/-</sup>* PCA-bearing mice developed metastasis during the same observation period (data not shown).

Having demonstrated the distinctly different metastatic potential of the *Pten<sup>pc-/-</sup>*, *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>*, and *Pten<sup>pc-/-</sup> p53<sup>pc-/-</sup>* models, we then compared transcriptomes of primary PCAs from each to gain insight into the molecular determinants of their phenotypic differences. First, primary anterior prostate tumours with comparable sizes were harvested from 15-week-old animals from each model for mRNA profiling. Comparisons of *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* ( $n = 5$ ) versus *Pten<sup>pc-/-</sup>* ( $n = 5$ ) or *Pten<sup>pc-/-</sup> p53<sup>pc-/-</sup>* ( $n = 3$ ) with *Pten<sup>pc-/-</sup>* ( $n = 5$ ) prostate tumour transcriptomes defined the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* or *Pten<sup>pc-/-</sup> p53<sup>pc-/-</sup>* signatures (Supplementary Data 2, 3). Ingenuity Pathway Analysis (IPA) was used to generate hypotheses on the biological processes that underlie the metastatic phenotype in the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* PCAs. In contrast to the *Pten<sup>pc-/-</sup> p53<sup>pc-/-</sup>* signatures, we found that the two most significantly enriched gene-categories in the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* signature are ‘cellular movement’ and ‘cellular growth and proliferation’ (Supplementary Fig. 9).

Enrichment of cell growth and proliferation genes in *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* PCA concurs with histopathological observations of markedly increased proliferation index relative to *Pten<sup>pc-/-</sup>* tumours (Fig. 3a, b). Increased proliferation index was not associated with changes in apoptosis (Supplementary Fig. 10), but rather neutralization of oncogene-induced senescence (OIS) as reflected by loss of senescence-associated  $\beta$ -galactosidase staining (Fig. 3a, b). A survey of key regulators of G1/S transition and OIS revealed significant induction of cyclin D1 protein but without significant changes in p53, p21 (also known as Cdkn1a)

and p27 (also known as Cdkn1b) in *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* relative to *Pten<sup>pc-/-</sup>* tumours (Fig. 3c and Supplementary Fig. 11). Complementing this hypothesis-driven survey, cyclin D1 was computationally identified as the only cell cycle regulator in the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* signature that both exhibits human PCA progression-correlated expression in Oncomine and harbours putative SMAD-binding elements (SBEs) in its promoter lifespan in the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* compared with the *Pten<sup>pc-/-</sup>* cohort. **c**, Gross anatomy of representative prostates at 22 weeks of age. Scale bar, 10 mm. **d**, H&E-stained sections and immunohistochemical analyses of primary PCA, lumbar lymph nodes and lung of *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>*. The tumour context is depicted in low-magnification insets. Scale bar, 50  $\mu$ m. (Supplementary Data 2). Indeed, chromatin immunoprecipitation (ChIP) assays confirmed that SMAD4 can bind to one of the SBEs in the cyclin D1 gene promoter (Supplementary Figs 12 and 13). Correspondingly, TGF $\beta$ 1 (also known as TGFB1)-treated SMAD4-transduced *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* prostate tumour cells show down-regulated cyclin D1 expression (Supplementary Fig. 14a). Finally, enforced cyclin D1 expression significantly enhanced xenograft tumour growth *in vivo* (Fig. 3d). Together, these data support the thesis that cyclin D1 is a key mediator of the cardinal tumour biological feature of increased proliferation in the metastatic *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* model.

We next obtained available ORFs corresponding to 21 of the 84 ‘Cellular Movement’ genes (Supplementary Table 2) and assayed their ability to enhance invasion of human prostate cancer cells. Using the modified Boyden chamber assay, 10/21 ORFs enhanced invasion of prostate cancer cells including PC3 (Supplementary Table 2). Among these validated invasion genes, *SPP1* was selected for deeper analysis given its PCA progression-correlated expression in Oncomine, its prognostic potential for BCR in univariate COX proportional hazard analysis in a data set comprising of transcriptome and outcome data on 79 PCA patients (Supplementary Tables 3 and 4)<sup>13</sup>, and its known link to TGF $\beta$  signalling under different cellular contexts<sup>1–6</sup>. Western blotting and immunohistochemical analyses confirmed increased Spp1 expression in *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* compared to *Pten<sup>pc-/-</sup>* tumours (Fig. 3c and Supplementary Fig. 11) and promoter analysis<sup>17</sup> identified a conserved SBE in the *Spp1* promoter which was confirmed by ChIP assay in cells treated with TGF $\beta$ 1 (Supplementary Fig. 15). In contrast to previous studies showing Smad4 as an inducer of *Spp1* expression through displacement of transcription repressors from *Spp1* promoter in a mink lung epithelial cell line and a preosteoblastic cell line<sup>14,16</sup>, loss of *Smad4* in the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* prostate tumour cells results in markedly increased Spp1 expression (Fig. 3c and Supplementary Data 2). TGF $\beta$ 1 treatment correspondingly suppressed *Spp1* expression in SMAD4-dependent manner in *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* prostate tumour cells (Supplementary Fig. 14b). These observations underscore the context-specific actions of TGF $\beta$ -SMAD4 signalling on its downstream targets<sup>18</sup>. Next, to verify that Spp1 functionally contributes to the metastatic phenotype in our model, we showed significant inhibition of invasive activity *in vitro* upon knockdown of *Spp1* in *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* mouse PCA cells (Supplementary Fig. 16). Conversely, enforced SPP1 expression enhanced invasion *in vitro* of several human lines (Supplementary Fig. 17). Finally, orthotopic implantation of SPP1-transduced PC3 cells in the prostate exhibited increased lumbar lymph node metastasis and enhanced metastasis to lung (Fig. 3e–f and Supplementary Fig. 18). These results strongly indicated that *SPP1* is a pro-metastasis invasion gene in human PCA and in the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* PCA model.

The *in vivo* genetic modelling studies, the *in silico* transcriptomic and pathway analyses, along with the tumour biological and functional characterizations collectively point to the inactivation of *Pten* and *Smad4* as well as activation of cyclin D1 (also known as Cnd1) and Spp1 as drivers of PCA progression. As such, we posited that these four key PCA metastasis progression relevant genes may carry prognostic value for metastasis risk in human PCA (see Supplementary Fig. 19). To this end, we assessed how robustly these four

genes can stratify risk of BCR ( $> 0.2 \text{ ng ml}^{-1}$ ) in the data set from ref. 13. Although only *SPP1* was significantly correlated with BCR in univariate analysis, an overall risk score integrating the four-gene signature by multivariate Cox regression showed significant association with BCR as well ( $P$ -value = 0.0025, and overall  $C$ -index = 0.66, see Supplementary Tables 4 and 5). Furthermore, the four-gene model robustly stratified the ref. 13 cohort by  $K$ -mean clustering into two groups that exhibited significant difference in risk for BCR by Kaplan–Meier analysis (Fig. 4a; hazard ratio = 2.6, log-rank test  $P$  = 0.012). Importantly, by  $C$ -statistics, this four-gene signature carries independent prognostic information as it can enhance the prognostic accuracy of Gleason score from  $C$ -index from 0.77 to 0.8 (Fig. 4b), even though by itself, the four-gene signature ( $C$ -index as 0.75) performs only as well as Gleason score alone (Fig. 4b).

We repeated this analysis in an independent extreme-case-control cohort derived from the Physicians' Health Study (PHS) (Supplementary Table 6; see Methods for study design), where we showed that the four-gene model was also capable of enhancing the prognostic accuracy of Gleason score in predicting metastatic lethal outcome (Fig. 4c;  $C$  = 0.716 by four-gene signature). Although exclusion of non-informative cases may have biased towards a positive association, the prognostic performance by this four-gene signature is unlikely a chance occurrence because, by gene-set-enrichment testing, it outperforms 243 other bidirectional signatures curated in the Molecular Signature Databases of the Broad Institute (MSigDB, version 2.5) in predicting metastatic lethal outcome in this PHS extreme-case-control cohort (Supplementary Fig. 20).

Encouraged by the prognostic value in two independent cohorts using RNA expression yet mindful of the inherent intra-tumoural heterogeneity of PCA which may obscure expression differences in whole-tumour transcriptome profiles, we next performed immunohistochemical staining with validated antibodies against PTEN, SMAD4, cyclin D1 and SPP1 on a tumour tissue microarrays (TMA) comprising a cohort of 405 tumour specimens randomly selected from men diagnosed with prostate cancer who underwent radical prostatectomy in the PHS cohort. Staining results were quantified by expert pathologists (R.L. and M.L.) blinded to the outcome of the cases. Indeed, not only does the four-protein model improve the prognostic accuracy of Gleason score in combination, it performs significantly better than Gleason score alone (Fig. 4d;  $C$  = 0.774 for Gleason only,  $C$  = 0.829 for four-protein model alone, and  $C$  = 0.882 for Gleason + four-protein model;  $P$  = 0.015 for improvement). Moreover, the addition of the four-protein model to the clinical parameters (Gleason, age at diagnosis, TNM stage;  $C$  = 0.842) leads to a significant seven point increase in the  $C$ -statistic ( $C$  = 0.913),  $P$ -value for difference between full clinical model versus clinical model + four-protein signature = 0.047 (Supplementary Table 7). The enhanced prognostic value of 'Gleason + four-protein model' was similarly validated in yet another independent cohort, the Directors Challenge TMA containing 40 prostate cancer patients with recurrence as outcome (Supplementary Table 8) (Fig. 4e and Supplementary Fig. 19c;  $C$  = 0.704 for Gleason alone versus  $C$  = 0.740 for Gleason + four-protein model).

In summary, concomitant *Pten* and *Smad4* inactivation in the prostate epithelium can bypass OIS, enhance tumour cell proliferation and drive invasion to produce a fully-penetrant invasive and metastatic PCA phenotype in the mouse (Supplementary Fig. 21). The human relevance of this *Pten*<sup>pc-/-</sup> *Smad4*<sup>pc-/-</sup> model of metastatic PCA is credentialed by the prognostic significance of a four-marker signature derived from this mouse model in predicting biochemical recurrence or lethal metastasis in human PCAs. Thus this study will facilitate the development of a molecularly-based prognostic assay that may complement the current standard of care to improve evidence-based management of PCA patients, a current major unmet need.

## Methods

### ***Pten* and *Smad4* conditional alleles, genotyping and expression analysis**

The *Pten<sup>loxP</sup>* and *Smad4<sup>loxP</sup>* conditional knockout alleles have been described elsewhere<sup>21,22</sup>. *p53<sup>loxP</sup>* strain was generously provided by A. Berns<sup>23</sup>. Prostate epithelium-specific deletion was effected by the PB-Cre<sup>24</sup> and was obtained from MMHCC ([http://mouse.ncifcrf.gov/search\\_results.asp](http://mouse.ncifcrf.gov/search_results.asp)). All cohorts were in a FVB/n, C57BL/6 and 129/Sv mixed genetic background.

### **Tissue analysis**

Normal and tumour tissues were fixed in 10% neutral-buffered formalin overnight then processed, paraffin-embedded, sectioned and stained with haematoxylin and eosin according to standard protocol. For immunohisto-chemistry, 5 µm sections were incubated with primary antibodies overnight at 4 °C in a humidified chamber. Primary antibodies: rabbit polyclonal anti-androgen receptor (06-680, Millipore), Smad4 (1676-1, Epitomics), Ck8 (also known as Krt8) (GTX15465, GeneTex); p53 (VP-P956, Vector Laboratories), p21 (C-19, sc-397, Santa Cruz), p27 (2747-1, Epitomics) and Cyclin D1 (RM-9104-R7, Thermo Scientific); and mouse monoclonal Spp1 (sc-21742, Santa Cruz). For rabbit antibodies, sections were subsequently developed using Dako Envision. Mouse monoclonal staining was developed using MOM kit (Vector). To assay senescence in prostate tissue of the various genotypes, frozen sections were stained for SA-β-Gal as described elsewhere<sup>7</sup>. Representative sections from at least three mice were counted for each genotype.

For western blot analysis, tissues and cells were lysed in RIPA buffer (20 mM Tris pH 7.5, 150 mM sodium chloride, 1% Nonidet P-40, 0.5% sodium deoxycholate, 1 mM EDTA, 0.1% SDS) containing complete mini protease inhibitors (Roche) and phosphatase inhibitors. Western blots were obtained using 20–50 µg of lysate protein, and were incubated with antibodies against Smad4 (sc-7966, Santa Cruz), phospho-Akt<sup>Ser473</sup> (4060, Cell Signaling Technology), Akt (3272, Cell Signaling Technology), V5 (R960-25, Invitrogen), Hsp70 (610607, BD Transduction Laboratories), and Spp1 (sc-21742, Santa Cruz), p53 (sc-6243, Santa Cruz), p27 (2747-1, Epitomics), p21 (65961A, BD Biosciences), Cyclin D1 (2926, Cell Signaling), pSmad1/5/8 (9511, Cell Signaling), Smad1 (9743, Cell Signaling), pSmad2 (Ser465/467) (3101S, Cell Signaling), Smad2 (3103, Cell Signaling), pSmad3 (ab52903, Abcam), Smad3 (06-920, Millipore).

### **Establishment of mouse prostate tumour cell lines**

Tumours were dissected from prostates of *Pten<sup>loxP/loxP</sup> Smad4<sup>loxP/loxP</sup> PB-Cre4<sup>+</sup> (Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>)* mice, minced, and digested with 0.5% type I collagenase (Invitrogen) as described previously. After filtering through a 40-µm mesh, the trapped fragments were plated in tissue culture dishes coated with type I collagen (BD Pharmingen). Cells with typical epithelial morphology were collected, and single cells were seeded into each well of a 96-well plate. Three independent cell lines (*Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>*-1, -2 and -3,) were established and maintained in DMEM plus 10% fetal bovine serum (FBS, Omega Scientific), 25 µg ml<sup>-1</sup> bovine pituitary extract, 5 µg ml<sup>-1</sup> bovine insulin, and 6 ng ml<sup>-1</sup> recombinant human epidermal growth factor (Sigma-Aldrich). The prostate tumour epithelial cells express epithelial marker CK8 detected by immunofluorescence analyses using CK8 (GTX15465, GeneTex) antibody.

### **Establishment of inducible *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup> SMAD4-TetOn* cell lines**

*Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* prostate tumour cells (see above) were used as parental cells for establishment of inducible SMAD4 TetOn cells using TetOn Advanced Inducible Gene Expression System (Clontech). Human *SMAD4* coding region inserted into the pTRE-Tight

vector, and a TetOn SMAD4 expression system was generated according to the manufacturer's protocol. Stable clones were induced to express SMAD4 using 1  $\mu\text{g ml}^{-1}$  doxycycline (dox), and expression was verified to be comparable to the SMAD4 level in *Pten<sup>pc-/-</sup>* prostate tumours by western blot analysis of whole-cell extracts, using anti-SMAD4 antibody (sc-21742, Santa Cruz) (Supplementary Fig. 12).

### RNA isolation and real-time PCR

Total RNA was extracted using TRIzol followed by RNeasy Mini kit (Qiagen) cleanup and RQ1 RNase-free DNase Set treatment (Promega) according to the manufacturer's instructions. First strand cDNA was synthesized using 1  $\mu\text{g}$  of total RNA and Superscript II (Invitrogen). Real-time quantitative PCR was performed in triplicates with a MxPro3000 and SYBR GreenER qPCR mix (Invitrogen). The relative amount of specific mRNA was normalized to *Gapdh*. Primer sequences are available upon request.

### Transcriptomic and pathway analyses

For transcriptomic analyses, anterior prostate from mice at 15 weeks of age were isolated and total mRNA extracted, labelled and hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 Arrays by the Dana-Farber Cancer Institute Microarray Core Facility according to the manufacturer's protocol. Affymetrix mouse MOE430 raw data (CEL files) were pre-processed using robust multi-array analysis (RMA) of the Affy package of Bioconductor. The background-corrected, normalized and summarized probe set intensity data were then analysed using significance analysis of microarrays (SAM) to identify differentially expressed genes. Using a twofold, FDR 5% cut-off, we generated a 3,532 probe set that distinguishes differentially expressed genes in anterior prostate samples from *Pten<sup>pc-/-</sup>* (five mice) versus WT (PB-Cre4) (three mice), 397 probe sets that distinguishes differentially expressed genes in anterior prostate samples from *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* (five mice) versus *Pten<sup>pc-/-</sup>* (five mice), and 370 probe sets that distinguishes differentially expressed genes in *Pten<sup>pc-/-</sup> p53<sup>pc-/-</sup>* (three mice) versus *Pten<sup>pc-/-</sup>* (five mice). Gene information for all probes was annotated based on 'Mouse430\_2.na28.annot.csv' downloaded from the Affymetrix website. Probes with multiple genes in the Affymetrix annotation file were mapped against latest mouse genome build (UCSC mm9) for the single matching gene. Probes mapped to more than one position on mm9 were ignored. Human orthologues of mouse genes were extracted from HomoloGene build 64 (<http://ftp.ncbi.nih.gov/pub/HomoloGene/>). Intersection of the murine list with the human orthologous genes produced an orthologous set of genes.

All differentially expressed gene lists generated as described above were further analysed with the Ingenuity Pathways Analysis program (<http://www.ingenuity.com/index.html>) to identify canonical pathways, and molecular and cellular functions enriched in the related gene lists.

### cDNA and shRNA constructs

Human cDNAs presented in Supplementary Table 1 were obtained from the Human ORFeome collection, Japan National Institute of Technology and Evaluation (NITE), Japan, and transferred into a modified pMSCV-V5 vector via Gateway recombination. Knockdown of human *SMAD4* and mouse *Spp1* were performed by infecting the indicated cells with lentivirus containing either *shSMAD4* or *shSpp1* (provided by W. Hahn). The shRNA constructs for *shSMAD4* #1, #2 correspond to clone ID#s TRCN0000040028 (hairpin sequence: CCGGGCAGACAGAACTGGATTAAGTTCGAGTTTAATCCAGT TTCTGTCTGCTTTTTG), and TRCN0000040029 (hairpin sequence: CCGGCC TGAGTATTGGTGTTCATTCTCGAGAATGGAACACCAATACTCAGGTT TTTG), respectively. The shRNA constructs for *shSpp1* #1, #2 correspond to clone ID#s TRCN0000054698 (Hairpin sequence: CCGGCTCTTAGCTTA

GTCTGTTGTTCTCGAGAACAACAGACTAAGCTAAGAGTTTTTG), and TRCN0000054700 (Hairpin sequence: CCGGCACAAGGACAAGCTAGTCC TACTCGAGTAGGACTAGCTTGTCTTGTGTTTTTG), respectively, in the RNAi Consortium (TRC).

### Viral production and transduction

Approximately  $2 \times 10^6$  293T cells were seeded in 100 mm plates 15h before transfection (~30% confluent) in 10% FBS/DMEM with antibiotics. For MSCV viral production, 3  $\mu\text{g}$  viral backbone, 2.7  $\mu\text{g}$  gag/pol expression vectors, and 0.3  $\mu\text{g}$  VSV-G expression vector were diluted to 20  $\mu\text{l}$  using Opti-MEM (Invitrogen) and combined with 180ml Opti-MEM containing 12  $\mu\text{l}$  FuGENE-6 (Roche). This mixture was incubated at room temperature (RT) for 20 min and added to the 10 ml media covering the 293T cells. For pLKO shRNA lentivirus production, 10  $\mu\text{g}$  of viral backbone and 10  $\mu\text{g}$  of lentiviral packaging vectors were diluted to 1,000  $\mu\text{l}$  using Opti-MEM (Invitrogen). The resulting mix was combined with 1,000  $\mu\text{l}$  Opti-MEM containing 30  $\mu\text{l}$  Liptofectamine2000 (Invitrogen), incubated at room temperature for 20 min and added to 8 ml media covering the 293T cells. The media was replaced with 10% FBS/DMEM approximately 10 h post-transfection and viral supernatants were collected at 36 h and 60 h after transfection and combined. Viral supernatants (5 ml) containing 8  $\mu\text{g ml}^{-1}$  polybrene were added to target cells that were seeded 24 h before infection at 70–80% confluence. Cells were infected twice and allowed to recover in 10% FBS/RPMI 1640 with antibiotics for 12 h following the second infection, after which cells were selected with 2  $\mu\text{g ml}^{-1}$  puromycin for 4 days and allowed to recover in normal medium for 24 h before further experiments.

### Transwell invasion assay

Standard 24-well Boyden invasion chambers (BD Biosciences) were used to assess cell invasiveness following the manufacturer's suggestions. Briefly, cells were trypsinized, rinsed twice with PBS, resuspended in serum-free media, and seeded at  $2 \times 10^5$  cells per well for PC3 cells and *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* cells,  $4 \times 10^5$  cells per well for BPH1 cells. Chambers in triplicate were placed in 10% serum-containing media as a chemo-attractant and an equal number of cells were seeded in cell culture plates in triplicate as input controls. Following 22 h incubation, chambers were fixed in 10% formalin, stained with crystal violet for manual counting or by pixel quantification with Adobe Photoshop. Data was normalized to input cells to control for differences in cell number (loading control).

### Orthotopic and renal capsule implantation

Male SCID mice (6 weeks old) were obtained from Taconic. Orthotopic and renal capsule implantations were performed as described previously<sup>25,26</sup>. Briefly, a suspension of  $1 \times 10^6$  cells in 50  $\mu\text{l}$  of a 1:1 mixture of PBS and Matrigel (BD Biosciences) was injected into the anterior prostate lobe. For renal capsule implantation  $5 \times 10^5$  cells were suspended in 50  $\mu\text{l}$  of neutralized type I rat tail collagen (BD Biosciences), allowed to gel at 37 °C for 15min, covered with growth medium, followed by grafting beneath the renal capsule of mice.

### Identification of putative SMAD binding sites (SBEs)

The Smad binding elements (SBEs) in the promoters of the *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* signature of 267 genes were identified computationally by established methods<sup>16</sup>. Briefly, the conserved nucleotides in the 4kb promoter regions of the promoters were isolated and scanned for enrichment of the SMAD binding motifs in TRANSFAC. Enrichment was assessed by comparing the target regions to matched control regions at the same distance from the transcription start sites of random genes. Promoter analysis on these gene sets for SBEs used the CisGenome software (<http://www.biostat.jhsph.edu/~hji/cisgenome/>).



## Chromatin immunoprecipitation (ChIP) assay

ChIP assays with 1 µg of normal mouse IgG (Upstate), normal rabbit IgG (Upstate), anti-RNA polymerase II (PoII) (Upstate), anti-acetyl-Histone H3 (Upstate) or anti-SMAD4 IgG (mouse monoclonal, clone B8, sc-7966, Santa Cruz) overnight at 4 °C were conducted by established methods<sup>16</sup>.

## Immunohistochemical evaluation of outcome tissue microarrays (TMAs)

Immunohistochemical staining was performed on 5-µm sections of the TMAs to assess cytoplasmic PTEN (PN37, rabbit polyclonal, 18-0256, Zymed), cytoplasmic SMAD4 (mouse monoclonal, clone B8, sc-7966, Santa Cruz), nuclear cyclin D1 (Rabbit monoclonal, SP4, RM-9104-R7, Thermo Scientific), and cytoplasmic SPP1 expression (Rabbit polyclonal, O17, 18625, IBL) after citrate-based antigen retrieval.

TMA slides were scanned using the CRi Nuance v2.8 (Woburn) slide scanner following the standard bright field TMA protocol. The system acquires images at 20nm intervals and combines them into a stack file which represents one image. This was done automatically to create one image for each core on the TMA. The maximum likelihood method was used to extract the spectra of DAB and haematoxylin, which represent the different elements of IHC. inForm v0.4.2 software (CRi) was used to analyse the spectral images of each core. Initially, a training set comprising two classes of tissue was created: 'tumor' and 'other'. Representative areas for each class were marked on 12–16 images from each TMA. The software was trained on these areas using the spectra of both the counterstain (haematoxylin) and the immunostain (DAB) and tested to determine how accurate it could differentiate between the two classes. This process was repeated until further iterations no longer improved accuracy.

Histological images were then analysed using the 'nuclear or cytoplasmic' algorithm. The multispectral imaging capabilities of the Nuance slide scanner allows the software to isolate or segment the nuclei using the unmixed spectra of the nuclear counterstain and the DAB immunohistochemical stain used in addition for a nuclear biomarker. In turn, cytoplasm is found based on the non-nuclear tumour area. Threshold settings approximated: scale1, offset subtraction0, minimum blob size 30, maximum blob size 10,000, circularity threshold 0, edge sharpness 0, fill hole enabled (nuclear parameters); algorithm 4, area 200, compactness 0.5, Wht threshold 225 (cytoplasmic parameters). The final score was based on the percentage of the cytoplasmic or nuclear tumour area that was positively stained and this was represented as a ten bin histogram. This involved each pixel being placed into one of ten bins based on the intensity of the DAB spectra, with an adjustment of the threshold for the 9th bin by the user in order to create a desirable distribution. By reviewing images and their scores, a threshold level of these bins was determined that represented real staining, and the values from the bins above this threshold were added together to create a final score which represented the per-centage of cytoplasmic or nuclear area that was positively stained. All samples were also reviewed by pathologists (R.L. and M.L.) to ensure that assigned scores were appropriate. TMA cores that were difficult to classify (due to technical artefacts such as folds in the tissue, air bubbles, cores overlapping or due to difficulty in morphological classification) were either eliminated from the analysis in order to categorize the tissue appropriately. The Directors Challenge TMA originally contained 52 patient samples<sup>27</sup>. However, as is typical of most heavily used TMAs, some of the samples become exhausted over time from extensive use by the M.L. lab and the community. After careful quality control of each core on the TMA by R.L. in M.L. lab, only 40 high quality core samples were considered usable (Supplementary Table 7). Careful quality control of each core on the PHS TMA by R.L. in the M.L. lab, 405 high quality core samples were considered usable (Supplementary Table 5).

## Clinical outcome analysis

The raw Affymetrix HG-U133A expression profiles and clinical information of 79 prostate cancer patients from the ref. 13 cohort (Supplementary Table 2)<sup>12</sup> were generously provided by W. Gerald. The raw data set was analysed by MAS5 algorithm. Low-expression probesets with less than 20% present calls across the 79 samples were excluded from the data. The remaining 13,027 probesets map to 8,763 genes with unique symbols, and the mean log-transformed probeset levels were used as the gene expression profiles.

A univariate Cox proportional hazard analysis was conducted using the R ‘survival’ package for invasion assay positive genes to identify those expression in PCA tumours was positively associated with biochemical recurrence (BCR, defined by post-op PSA > 0.2 ng ml<sup>-1</sup>) in the ref. 13 data set<sup>12</sup>.

*K*-means clustering algorithm was used with the *PTEN/SMAD4/CCND1/SPP1* four-gene model to identify two cancer sample clusters. The initial centres for the *K*-means clustering were set at the two cases with the longest Euclidean distance. Kaplan–Meier analysis for the survival difference of the two cancer patient clusters was conducted using the R ‘survival’ package. *C*-statistics analysis was conducted using the R ‘survcomp’ package. The statistical procedures used in the analyses include a bootstrapping step that estimates the distribution of *C*-statistics of all models across 10,000 random bootstrapping instances, and a comparative step that uses the paired *t*-test to compare the *C*-statistics of models and evaluate the statistical significance<sup>28</sup>. Multivariate Cox proportional hazards model analysis with the four-gene signature was used to estimate the coefficients of individual genes, which combined the four-gene expression levels into an integrated risk score model defined.

To validate further the prognostic significance of this four-gene model, we repeated this analysis in an independent cohort derived from the Directors Challenge cohort<sup>27</sup> (Supplementary Table 7) and the Physicians' Health Study (PHS) cohort (Supplementary Table 5): the men with prostate cancer included in this study were participants in the Physicians' Health Study (PHS), an ongoing randomized trial among US male physicians<sup>29,30</sup>. The men were diagnosed with histologically-confirmed prostate cancer after randomization, between January 1983 and December 2004. We obtained archival formalin-fixed, paraffin-embedded tissue specimens, either radical prostatectomy (95%) or TURP (5%) and constructed tumour tissue microarrays for immunohistochemical analyses; 405 had sufficient tumour tissue available for this project. All men in the trial were followed for mortality, and cause of death was confirmed by a study endpoints committee. In addition, we retrieved medical records and questionnaire data on the men with prostate cancer to collect information on treatments, clinical characteristics, as well progression of the cancer. Through March 2010, 38 men of 405 had developed a lethal metastatic phenotype, defined by bony metastases or cancer-specific death.

We undertook gene expression profiling as part of a previous project to define molecular signatures in prostate cancer<sup>31</sup> on a subset of the PHS included on the TMAs. As part of the sampling, we sought to maximize efficiency for studies of lethal prostate cancer by devising a study design that included men who either died from prostate cancer or developed metastases during follow up (‘lethal prostate cancer’ cases) or who survived at least 10 years after their diagnosis without any evidence of metastases (men with ‘indolent prostate cancer’). We sought to include all lethal cancers, based on follow-up through March 2007, and took a random sample of indolent cancers for a total sample size of 116 cases. In this design, we exclude men with non-informative outcomes, namely those who died from other causes within 10 years of their prostate cancer diagnosis or had been followed for less than 10 years with no disease progression. The natural history of prostate cancer is quite long, with men dying of prostate cancer even 15 or more years after cancer diagnosis<sup>32</sup>. Thus, we

excluded prostate cancer cases with less than 10 years follow-up to increase confidence on the outcome annotation since we are not seeking to estimate survival time. By focusing on long-follow-up cases, an extreme-case-control study design allows us to maximally identify lethal versus indolent prostate cancer. In addition, to minimize the potential that *C*-statistics estimation might be biased towards a higher lethal composition by such extreme-case-study-design, we have chosen a logistic regression analysis rather than survival analysis.

The tissue based studies were approved by the Institutional Review Boards of Harvard School of Public Health and Partners Healthcare.

We assessed the enrichment of the four-gene signature to that of 244 bidirectional signatures curated in the Molecular Signature Databases of the Broad Institute (MSigDB, version 2.5) by computing an enrichment statistic<sup>33</sup>.

## Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

## Acknowledgments


The authors are grateful to the late W. Gerald for providing the primary gene expression data and clinical outcome files<sup>13</sup>. We thank S. Zhou for excellent mouse husbandry and care, B. Xiong and G. Tonon for bioinformatic assistance, and S. Jia, J. M. Stommel, J. Paik, M. Kim and A. C. Kimmelman for helpful discussion. We thank M. Vidal, the Ellison Foundation and DFCI ISR for support of ORF cloning efforts, R. Maser for MSCV-puro-v5 gateway vector, W. Hahn for shRNA constructs. We thank the DF/HCC Specialized Histopathology Core and the DF/HCC Tissue Microarray and Imaging core for the TMA IHC staining; the DFCI/BWH Center for Molecular Oncologic Pathology (CMOP) for the quantification of the IHC. Z.D was supported by the Damon Runyon Cancer Research Foundation. D.H. was supported by a graduate fellowship from the National Science Foundation. H.Z. was supported by the Helen Hay Whitney Foundation. Y.A.W. was supported by the Multiple Myeloma Research Foundation. This work is supported by the Belfer Institute for Applied Cancer Science, NCI U01-CA84313 (L.C. and R.A.D.), DF/HCC SPORE in Prostate Cancer P50 CA090381-08 (Z.D.), the National Cancer Institute (M.L. RO1CA131945 and P50 CA90381, L.M. RO1 5R01CA136578, M.S. R01CA141298), and the Linda and Arthur Gelb Center for Translational Research (M.L.). R.A.D. was supported by an American Cancer Society Research Professorship and L.M. was supported by the Prostate Cancer Foundation.

## References

1. Andreou M, Cheng L. Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. *Hum Pathol.* 2010; 41:781–793. [PubMed: 20466122]
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin.* 2010
3. Walsh PC, DeWeese TL, Eisenberger MA. Localized prostate cancer. *N Engl J Med.* 2007; 357:2696–2705. [PubMed: 18160689]
4. Rubin MA. Targeted therapy of cancer: new roles for pathologists—prostate cancer. *Mod Pathol.* 2008; 21(Suppl 2):S44–S55. [PubMed: 18437173]
5. Taylor BS, et al. Integrative genomic profiling of human prostate cancer. *Cancer Cell.* 2010; 18:11–22. [PubMed: 20579941]
6. Jeet V, Russell PJ, Khatri A. Modeling prostate cancer: a perspective on transgenic mouse models. *Cancer Metastasis Rev.* 2010; 29:123–142. [PubMed: 20143131]
7. Wang S, et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. *Cancer Cell.* 2003; 4:209–221. [PubMed: 14522255]
8. Chen Z, et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. *Nature.* 2005; 436:725–730. [PubMed: 16079851]
9. Trotman LC, et al. Pten dose dictates cancer progression in the prostate. *PLoS Biol.* 2003; 1:E59. [PubMed: 14691534]


10. Ma X, et al. Targeted biallelic inactivation of *Pten* in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis. *Cancer Res.* 2005; 65:5730–5739. [PubMed: 15994948]
11. Zeng L, Rowland RG, Lele SM, Kyprianou N. Apoptosis incidence and protein expression of p53, TGF-beta receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate. *Hum Pathol.* 2004; 35:290–297. [PubMed: 15017584]
12. Aitchison AA, et al. Promoter methylation correlates with reduced Smad4 expression in advanced prostate cancer. *Prostate.* 2008; 68:661–674. [PubMed: 18213629]
13. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. *J Clin Invest.* 2004; 113:913–923. [PubMed: 15067324]
14. Hullinger TG, Pan Q, Viswanathan HL, Somerman MJ. TGFβ and BMP-2 activation of the OPN promoter: roles of Smad- and Hox-binding elements. *Exp Cell Res.* 2001; 262:69–74. [PubMed: 11120606]
15. Packer L, et al. Osteopontin is a downstream effector of the PI3-kinase pathway in melanomas that is inversely correlated with functional PTEN. *Carcinogenesis.* 2006; 27:1778–1786. [PubMed: 16571650]
16. Shi X, Bai S, Li L, Cao X. Hoxa-9 represses transforming growth factor-β-induced osteopontin gene transcription. *J Biol Chem.* 2001; 276:850–855. [PubMed: 11042172]
17. Paik JH, et al. FoxOs cooperatively regulate diverse pathways governing neural stem cell homeostasis. *Cell Stem Cell.* 2009; 5:540–553. [PubMed: 19896444]
18. Massague J, Seoane J, Wotton D. Smad transcription factors. *Genes Dev.* 2005; 19:2783–2810. [PubMed: 16322555]
19. Yu YP, et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. *J Clin Oncol.* 2004; 22:2790–2799. [PubMed: 15254046]
20. Dhanasekaran SM, et al. Delineation of prognostic biomarkers in prostate cancer. *Nature.* 2001; 412:822–826. [PubMed: 11518967]
21. Bardeesy N, et al. *Smad4* is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. *Genes Dev.* 2006; 20:3130–3146. [PubMed: 17114584]
22. Zheng H, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. *Nature.* 2008; 455:1129–1133. [PubMed: 18948956]
23. Marino S, Vooijs M, van der Gulden H, Jonkers J, Berns A. Induction of medulloblastomas in *p53*-null mutant mice by somatic inactivation of *Rb* in the external granular layer cells of the cerebellum. *Genes Dev.* 2000; 14:994–1004. [PubMed: 10783170]
24. Wu X, et al. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. *Mech Dev.* 2001; 101:61–69. [PubMed: 11231059]
25. Berger R, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. *Cancer Res.* 2004; 64:8867–8875. [PubMed: 15604246]
26. Wang Y, et al. A human prostatic epithelial model of hormonal carcinogenesis. *Cancer Res.* 2001; 61:6064–6072. [PubMed: 11507055]
27. Singh D, et al. Gene expression correlates of clinical prostate cancer behavior. *Cancer Cell.* 2002; 1:203–209. [PubMed: 12086878]
28. Haibe-Kains B, Desmedt C, Sotiriou C, Bontempi G. A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? *Bioinformatics.* 2008; 24:2200–2208. [PubMed: 18635567]
29. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. *N Engl J Med.* 1989; 321:129–135. [PubMed: 2664509]
30. Christen WG, Gaziano JM, Hennekens CH. Design of Physicians' Health Study II—a randomized trial of beta-carotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. *Ann Epidemiol.* 2000; 10:125–134. [PubMed: 10691066]

31. Sboner A, et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression. *BMC Med Genomics*. 2010; 3:8. [PubMed: 20233430]
32. Johansson JE, et al. Natural history of early, localized prostate cancer. *J Am Med Assoc*. 2004; 291:2713–2719.
33. Subramanian A, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci USA*. 2005; 102:15545–15550. [PubMed: 16199517]




**Figure 1. SMAD4 is a putative suppressor of prostate tumour progression**

**a, b**, Immunohistochemical (**a**) and western blot analysis (**b**) of wild-type (WT) and *Pten<sup>pc-/-</sup>* prostate tissues. Scale bar, 50  $\mu$ m. **c**, OncoPrint box plot of *SMAD4* expression levels between human PCA and metastasis in multiple data sets including those from ref. 19 and ref. 20. **d**, *SMAD4* knockdown enhanced metastatic potential to lung from PC3 cells implanted in renal capsule of immunocompromised nude mice.




**Figure 2. *Smad4* deletion drives progression of *Pten*-deficient prostate tumour to highly aggressive prostate cancer metastatic to lymph node and lung**  
**a**, Haematoxylin and eosin (H&E) stained sections of representative anterior prostates (AP) at 7, 11 and 15 weeks. Scale bar, 200  $\mu$ m. **b**, Kaplan–Meier cumulative survival analysis showing significant ( $P < 0.0001$ ) decrease in



**Figure 3. Ccnd1 and Spp1 are mediators of prostate tumour cell proliferation and metastasis**  
**a**, BrdU pulse-labelling and SA-β-galactosidase (β-Gal) staining of 15-week-old APs. **b**, Quantification of BrdU pulse labelling and β-Gal staining. Error bars represent s.d. for a representative experiment performed in triplicate. **c**, Western blot analysis demonstrating elevated Ccnd1 and Spp1 levels in *Pten<sup>pc-/-</sup> Smad4<sup>pc-/-</sup>* compared to *Pten<sup>pc-/-</sup>* prostate tumours. **d**, Enforced CCND1 expression significantly enhanced prostate xenograft tumour growth of PC3 cells. **e, f**, Enforced SPP1 expression significantly increases metastatic activity of PC3 cells from prostate xenograft to lumbar lymph nodes (**e**) and to lung (**f**).





**Figure 4. Prognostic potential of a four-gene signature in human PCA**

**a**, The four-gene set of *PTEN/SMAD4/CCND1/SPP1* can dichotomize PCA cases for BCR in the ref. 13 data set. **b**, **c**, *C*-statistic analysis revealed that this four-gene set can enhance the prognostic accuracy of Gleason score in the ref. 13 data set (**b**) and in an independent PHS cohort (**c**). **d**, TMA-based four-protein model also significantly improve the prognostic ability of Gleason ( $P = 0.015$ ) from the PHS cohort. **e**, Representative immunohistochemical staining with specific antibody against PTEN, SMAD4, CCND1 and SPP1 in the Directors Challenge TMA. Scale bar, 200  $\mu\text{m}$ .